$VACH News
Last published 5mo ago
- 5mo agoVACHVRXAVERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026GlobeNewswireBusiness combination transaction with Voyager Acquisition Corp. complete, creating a Nasdaq-listed, innovative biopharmaceutical company focused on next-generation cancer therapies of novel bispecific T-cell engagers
- 5mo agoVACHVERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase AgreementGlobeNewswireTransactions Provide Financial Flexibility to Advance Pipeline of Next Generation Cancer Therapies Comprised of Novel Bispecific T-cell Engagers (TCEs) and Antibody-Drug Conjugates (ADCs)Support Closing of Business
- 8mo agoVACHVoyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AGGlobeNewswireBROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: "VACHU," "VACH," "VACHW") ("Voyager" or the "Company") held the general meeting on March 12, 2026 and approved the previously
- 8mo agoVACHVERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.GlobeNewswireZURICH, SWITZERLAND – March 2, 2026 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies, today announced that its shareholders approved the merger between VERAXA and Veraxa Biotech
- 1y agoVACHVERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in ImmunologyGlobeNewswireZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY – September 30, 2025 -- VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.
- 1y agoVACHVERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SECGlobeNewswireZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG ("VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and
- 1y agoVACHVERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology PlatformGlobeNewswireZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")),
- 1y agoVACHVERAXA Biotech Appoints Rick Austin as Chief Scientific OfficerGlobeNewswireVERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), announced today the appointment of Rick
- 1y agoOABIVACHVERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate ProgramGlobeNewswireZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")),
- 1y agoVACHVACHUVACHWVERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer TherapiesGlobeNewswireVERAXA's Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE")
- 2y agoVACHVACHUVoyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024GlobeNewswireBROOKLYN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (NASDAQ:VACHU) (the "Company") announced that holders of the units sold in the Company's initial public offering of 25,300,000 units, which
- 2y agoVACHVACHUVoyager Acquisition Corp. Announces Closing of $253,000,000 Initial Public OfferingGlobeNewswireBROOKLYN, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (NASDAQ:VACHU) (the "Company") today announced that it closed its initial public offering of 25,300,000 units at $10.00 per unit, including
- 2y agoVACHVACHUVoyager Acquisition Corp. Announces Pricing of $220,000,000 Initial Public OfferingGlobeNewswireBROOKLYN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (NASDAQ:VACHU) (the "Company") announced today the pricing of its initial public offering of 22,000,000 units at $10.00 per unit. The units